Matches in Nanopublications for { ?s ?p ""ORILISSA is contraindicated in women: Who are pregnant [see Use in Specific Populations ( 8.1 With known osteoporosis because of the risk of further bone loss [see Warnings and Precautions ( 5.1 With severe hepatic impairment [see Use in Specific Populations ( 8.7 12.3 With concomitant use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine and gemfibrozil) [see Drug Interactions ( 7.2 Pregnancy ( 4 Known osteoporosis ( 4 Severe hepatic impairment ( 4 Strong organic anion transporting polypeptide (OATP) 1B1 inhibitors ( 4"" ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- association label ""ORILISSA is contraindicated in women: Who are pregnant [see Use in Specific Populations ( 8.1 With known osteoporosis because of the risk of further bone loss [see Warnings and Precautions ( 5.1 With severe hepatic impairment [see Use in Specific Populations ( 8.7 12.3 With concomitant use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine and gemfibrozil) [see Drug Interactions ( 7.2 Pregnancy ( 4 Known osteoporosis ( 4 Severe hepatic impairment ( 4 Strong organic anion transporting polypeptide (OATP) 1B1 inhibitors ( 4"" assertion.